A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women

Inclusion Criteria: * Woman is between 18 and 40 years of age * Has intact uterus and ovaries * Has regular menstrual cycles of 25-35 days duration * Able to comply with the protocol, including frequent blood sampling, and lives within the catchment area of the clinic * Understands the study procedures and agrees to participate in the study by giving written informed consent * Able to use non-hormonal, double-barrier contraceptives (e.g. condoms and diaphragm) with every act of intercourse, or has been sterilized with tubal ligation, or only male partner has been sterilized with vasectomy * Progesterone \>10 nmol/L in at least one sample in the lead-in cycle Exclusion Criteria: * All contraindications to OC use including * Thrombophlebitis or thromboembolic disorders * Past history of deep vein thrombophlebitis or thromboembolic disorders * Past or current cerebrovascular or coronary artery disease * Known or suspected carcinoma of the breast * Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia * Undiagnosed abnormal genital bleeding * Cholestatic jaundice of pregnancy or jaundice with prior pill use * Hepatic adenomas or carcinomas * Woman has a history of headaches with focal neurological symptoms * Known or suspected pregnancy * Aged \>35 and smoker * BMI \>29 * Positive urine pregnancy test at the screening or baseline visit * Desired pregnancy within the duration of the study * Known hypersensitivity to progestins * Known hypersensit…